Vector Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Q1 2024 Report May 30, 2024 Presenters Sofia Heigis, Chief Executive...

Q1 2024 Report May 30, 2024 Presenters Sofia Heigis, Chief Executive...

Japan, South Korea, and the African subcontinent are now covered by the Alliance. With the addition of two new WODA members – Nxera Pharma (formerly Sosei Heptares) and Veld Pharmaceuticals – WODA now provides access to over 200 million rare disease patients. TOKYO and ZUG, Switzerland, April 08, 2024 (GLOBE NEWSWIRE) -- The World Orphan Drug Alliance (WODA), a global alliance of commercial distributors dedicated to providing access to treatments for rare diseases and specialty medicines in comp

DUBAI, United Arab Emirates and STOCKHOLM, Sweden, March 27, 2024 (GLOBE NEWSWIRE) -- Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”) countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq. Under the terms of this e

Strategic roadmap to achieve blockbuster status for multiple products and expand the Company’s engine for future innovation COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 8, at the 42nd Annual J.P. Morgan Healthcare Conference. “With unwavering focus on our values of P